Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results, Misses Estimates By $0.03 EPS

Spero Therapeutics (NASDAQ:SPRO) released its earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), Zacks reports. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%.

Spero Therapeutics Trading Down 3.4 %

Shares of SPRO opened at $0.86 on Friday. The business’s 50-day moving average price is $0.82 and its 200 day moving average price is $1.06. The stock has a market capitalization of $46.89 million, a P/E ratio of 12.29 and a beta of 0.68. Spero Therapeutics has a 1-year low of $0.73 and a 1-year high of $1.81.

Insider Buying and Selling at Spero Therapeutics

In other Spero Therapeutics news, Director Ankit Mahadevia sold 69,219 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $53,990.82. Following the sale, the director now directly owns 689,866 shares of the company’s stock, valued at $538,095.48. The trade was a 9.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sath Shukla sold 155,333 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $121,159.74. Following the completion of the sale, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. The trade was a 8.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 245,241 shares of company stock valued at $191,288. 4.52% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a research note on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research report on Thursday, January 30th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.